Strykagen

Executive Summary

Strykagen Corp. is a preclinical-stage biotechnology company focused on developing small molecule therapies, diagnostics, and biomarkers for muscular dystrophies. Founded in 2018 and operating from laboratory space at the University of Nevada School of Medicine in San Diego, the company leverages modern molecular and cell biology tools to advance its pipeline. Despite being in early development, Strykagen addresses a significant unmet need in neuromuscular diseases, where treatment options remain limited. The company's private status and lack of disclosed funding or partnerships suggest it is still in the early research phase, with potential for future milestones as it progresses toward preclinical proof-of-concept studies.

Upcoming Catalysts (preview)

• TBDPreclinical Data Release in Animal Models25% success
• TBDLead Candidate Selection40% success
• TBDIND-Enabling Studies Initiation15% success